Hepatitis c treatments in current clinical development
8498 palavras
34 páginas
Hepatitis C Treatments in Current Clinical DevelopmentAlan Franciscus
Editor-in-Chief
Updated April 6, 2012
Drugs in Development – Direct Acting Antiviral (DAA) Combinations
Drugs in Development - General
HIV / HCV Coinfection Studies
Interferon Free Trials
Clinical Trial Process: Making Sense of Clinical Trials
How to Read an Abstract
Cancelled Trials
On Hold
To locate clinical trials go to www.clinicaltrials.gov – type in HCV or hepatitis C and drill down to studies that are listed by this resource.
Terms Used
Dosing:
BID = Taken twice a day
QD = Taken once a day
TID = Taken three times a day (every 7 to 9 hours)
Response:
RVR (Rapid virological response)= No virus detected at week 4 eRVR(Extended rapid virological response) = No virus detected at week 4 and week 12
EVR (Early Virological Response) — 2 log drop of HCV RNA after 12 weeks. cEVR = Complete Early Virological Response — No virus detected after 12 Weeks.
SVR12 (Sustained virological response) = No virus detected at 12 weeks after completion of treatment.
SVR24 = No virus detected at 24 weeks after completion of treatment.
1
Quick Reference Guide
Phase I
Drug Name
Drug Category
Company
ALS-2158
Polymerase Inhibitor
Alios
ALS-2200
Polymerase Inhibitor
Alios
ABT-072
Polymerase Inhibitor
Abbott
ABT-333
Polymerase Inhibitor
Abbott
ACH-2684
Protease Inhibitor
Achillion
ACH-2928
NS5A Inhibitor
Achillion
AZD-7295
NS5A Inhibitor
AstraZeneca
Clemizole
NS4B Inhibitor
Eiger BioPharmaceuticals
IDX719
NS5A Inhibitor
Idenix
ITX-5061
Entry Inhibitor
iTherX
MK-3281
Polymerase Inhibitor
Merck
PPI-461
NS5A Inhibitor
Presidio
PPI-688
NS5A Inhibitor
Presidio
TMC649128
Polymerase Inhibitor
Medivir / Tibotec
Note: Only drugs that have advanced into phase 2 and 3 studies will include comments
DAA Combinations
Drug Name/
Drug Name/
Category
Category
ABT-450 Protease ABT-072 Polymerase Inhibitor
Inhibitor
Company
Abbott / Enanta
ABT-450 Protease
Inhibitor